


Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50201/003002
	Serial No.	10/817,248
	Applicant	Abdel-Meguid et al.
	Filing Date	April 2, 2004
	Group	1654
	IDS Filed	December 28, 2005

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
ADK	Baird and Walsh, "The Interaction of Factor Xla with Activated Platelets but Not Endothelial Cells Promotes the Activation of Factor IX in the Consolidation Phase of Blood Coagulation," <i>The Journal of Biological Chemistry</i> 277:38462-38467 (2002).					
	Minnema et al., "Activation of Clotting Factor XI Without Detectable Contact Activation in Experimental Human Endotoxemia," <i>Blood</i> 92:3284-3301 (1998).					
	Salomon et al., "Prevalence, Causes, and Characterization of Factor XI Inhibitors in Patients with Inherited Factor XI Deficiency," <i>Blood</i> 101:4783-4788 (2003).					
ADK	Zivelin et al., "Factor XI Deficiency in French Basques is Caused Predominantly by an Ancestral Cys38Arg Mutation in the Factor XI Gene," <i>Blood</i> 99:2448-2454 (2002).					

EXAMINER 	DATE CONSIDERED <u>4/19/06</u>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



IRW/

PATENT
ATTORNEY DOCKET NO. 50201/003002

Certificate of Mailing: Date of Deposit: March 29, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Alexis L. Perry
Printed name of person mailing correspondence

[Signature]
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Abdel-Meguid et al. Art Unit: 1654
Serial No.: 10/817,248 Examiner: Kosar, Andrew D.
Filed: April 2, 2004 Customer No.: 21559
Title: COMPOUNDS AND METHODS FOR TREATMENT OF
THROMBOSIS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant discloses that a mature Factor XI polypeptide having the sequence set forth in SEQ ID NO: 15 but lacking the C-terminal alanine and valine residues at positions 606 and 607 formed crystals to the same extent as wild-type Factor XI.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the

04/03/2006 HBERHE 00000022 10817248

01 FC:1806

180.00 DP

NOT CONSIDERED
2/2/06 4/13/06


mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

March 29, 2004



Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045